<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04243057</url>
  </required_header>
  <id_info>
    <org_study_id>RWS-BTCH-001</org_study_id>
    <nct_id>NCT04243057</nct_id>
  </id_info>
  <brief_title>Diagnosis, Treatment Status and Prognosis of Cholangiocarcinoma in China: a Multicenter, Two-way, Non-intervention Study</brief_title>
  <official_title>Diagnosis, Treatment Status and Prognosis of Cholangiocarcinoma in China: a Multicenter, Two-way, Non-intervention Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tsinghua Chang Gung Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tsinghua Chang Gung Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, two-way, non-intervention study. the main purpose: Understand the
      current status of diagnosis and treatment of cholangiocarcinoma patients in China and observe
      the effect of different treatment options on patient recurrence and long-term survival

      Secondary purpose:

        1. Exploring the actual clinical treatment situation and its compliance with the existing
           diagnosis and treatment of bile duct cancer

        2. Exploring the establishment of clinical research standard fields and standards for
           diagnosis and treatment of bile duct cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>RFSR</measure>
    <time_frame>3 years</time_frame>
    <description>RFSR-Recurrence Free Survival Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>3 years</time_frame>
    <description>OS-Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RFS</measure>
    <time_frame>3 years</time_frame>
    <description>RFS-Recurrence Free Survival</description>
  </secondary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from 21 hospitals limit:5000
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. above the age of 18 years old, male or female

          2. clinical diagnosis of patients with cholangiocarcinoma

          3. Child-Pugh classification of A, B

          4. Eastern Cooperative Oncology Group scoring system (ECOG) score of 0-2 points

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaobin Feng, MD</last_name>
    <phone>+86 16601111975</phone>
    <email>fengxiaobin200708@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tsinghua Changgung Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>102218</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JiaHong Dong, MD</last_name>
      <phone>01056118763</phone>
      <email>dongjiahong@mail.tsinghua.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 24, 2020</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tsinghua Chang Gung Hospital</investigator_affiliation>
    <investigator_full_name>Dong Jiahong</investigator_full_name>
    <investigator_title>Executive President of Beijing Tsinghua Changgung Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

